Imprimis Pharmaceuticals Inc (IMMY)

2.68
NASDAQ : Health Care
Prev Close 2.68
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.65 / 4.69
Avg Volume 169.00K
Exchange NASDAQ
Shares Outstanding 20.07M
Market Cap 52.97M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Imprimis Pharmaceuticals Sells Pennsylvania Facility And Sinus Assets

Imprimis Pharmaceuticals Sells Pennsylvania Facility And Sinus Assets

Imprimis to focus resources on rapidly-growing core ophthalmology business

Eton Pharmaceuticals Names Sean Brynjelsen Chief Executive Officer And Director

Mr. Brynjelsen to lead development of Eton's proprietary sterile injectable branded product candidates

Eton Pharmaceuticals Announces $20 Million Series A Financing

Proceeds to support the development of Eton's proprietary corticotropin product candidate, Peyronie's Disease product candidate and other sterile injectable product candidates

Imprimis Pharmaceuticals And SightLife Surgical Sign Agreement For National Launch Of Serum Tears™

Imprimis begins roll-out of dry eye disease formulary with innovative autologous serum eye drop program

Imprimis Pharmaceuticals And Precision Lens Sign Agreement To Expand Imprimis' Ophthalmic Portfolio Market Opportunity In The U.S. Midwest

Largest distributor of ophthalmic products in the Midwest to expand Imprimis' ability to serve strategic accounts and accelerate growth

Imprimis Pharmaceuticals Acquires Exclusive License To Patented Ophthalmic Formulation For Dry Eye Disease

Formulation Expected to be a Cornerstone of Imprimis' New Dry Eye Program

Peer-Reviewed Paper Demonstrates The Benefits Of Dropless Cataract Surgery®

Compliance, cost-savings and efficacy listed as key reasons to adopt Dropless Therapy®

Imprimis Pharmaceuticals Begins Dispensing From FDA-Registered 503B Outsourcing Facility

Improved efficiencies and additional revenue opportunities expected for Imprimis' ophthalmic portfolio

EpiPen Price Relief Could Come From Rivals Before Politicians

EpiPen Price Relief Could Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

These 5 Under-$10 Stocks Are Set to Soar Higher

These 5 Under-$10 Stocks Are Set to Soar Higher

These under-$10 stocks look poised to break out and trade higher from current levels.

These 7 Stocks Under $10 Are Set to Soar Higher

These 7 Stocks Under $10 Are Set to Soar Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 3 stocks pushing the Drugs industry lower today.

Biotech Sector Performance February 2014: Red Hot But...

Biotech Sector Performance February 2014: Red Hot But...

An epic month of biotech stock performance ends with a significant sell off.

Imprimis Pharmaceuticals Innovates Back to Basics With Compounding

Imprimis Pharmaceuticals Innovates Back to Basics With Compounding

Few firms are positioned to take advantage of a custom Rx trend, but Imprimis has a helpful partner.

Faruqi & Faruqi, LLP Launches An Investigation Against Imprimis Pharmaceuticals, Inc. (IMMY) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Faruqi & Faruqi, LLP Launches An Investigation Against Imprimis Pharmaceuticals, Inc. (IMMY) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Imprimis Pharmaceuticals, Inc.

Ratings Changes To Be Publicly Issued on 5/31/13

Upgrades: ALJ, APWC, EXH, GTN.A, HCOM, LIWA, MOBI, OSTK, SWFT, TMS, VOC Downgrades: ACU, ADK, AXR, BRP, BXE, CAP, CITZ, CLMS, CRWN, CTIB, CVTI, DAVE, DYNT, EDGW, EMMS, ESTE, HTCO, IRIX, LMIA, LNBB, MASC, MCBI, MHH, MOC, NBBC, NOVB, NWPX, PMBC, PNRG, PZZI, RBCAA, RCKY, STRN, SYNL, TOWR, TWIN, UBCP, UMPQ, USAP, WLFC Initiations: AQ, IMMY Read on to get TheStreet Quant Ratings' detailed report:

2 Biotech Stocks Under $10 to Watch

2 Biotech Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.